Evogene (EVGN) Curent Deferred Tax Liability (2022 - 2023)

Evogene (EVGN) posted Curent Deferred Tax Liability of $10000.0 for Q3 2023, down 89.36% sequentially from $94000.0 in Q4 2022.

Evogene (EVGN) Curent Deferred Tax Liability (2022 - 2023) Analysis & Trends

Evogene has reported Curent Deferred Tax Liability for 2 years, with the latest figure at $10000.0 in Q3 2023.

Quarterly Curent Deferred Tax Liability changed N/A year-over-year to $10000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $10000.0 (changed N/A YoY) and the FY2022 annual result came in at $94000.0, changed N/A from the prior year.
Curent Deferred Tax Liability fell to $10000.0 in Q3 2023 per EVGN's latest filing, from $94000.0 in the prior quarter.
Over five years, Curent Deferred Tax Liability peaked at $94000.0 in Q4 2022 and troughed at $10000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Curent Deferred Tax Liability (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Evogene	4.38 Mn	4.38 Mn	204,000.00	-

Download Data